Due to the rigorous nature of the trial and enrollment interruptions caused by COVID-19, the study enrolled only 4 of the planned 110 subjects. Due to the lack of enrollment, the study was closed.

To evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension.

This is a prospective, randomized, double-blind, sham-controlled, multi-center post market study investigating the efficacy and safety of MobiusHD System, and the efficacy of the MobiusHD device in lowering mean systolic 24-hour ABP in subjects with resistant hypertension.

Inclusion Criteria:

• Aged 18-70 years;
• Diagnosed with resistant hypertension;
• A mean systolic 24-hour ABP of 135-170 mmHg following at least 30 days on a stable antihypertensive medication regimen (no changes in medications or dose).
• A mean systolic 24-hour ABP of 135-170 mmHg after washout of all antihypertensive medications.

Exclusion Criteria:

• Known or clinically suspected baroreflex failure or autonomic neuropathy
• Treatable cause of resistant hypertension
• Hypertension secondary to an identifiable and treatable cause other than sleep apnea